VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Tuesday, December 30, 2025

Stock Comparison

DSM-Firmenich AG vs Pfizer Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

DSM-Firmenich AG

DSFIR · Euronext Amsterdam

Market cap (USD)
SectorMaterials
CountryCH
Data as of2025-12-29
Moat score
63/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into DSM-Firmenich AG's moat claims, evidence, and risks.

View DSFIR analysis

Pfizer Inc.

PFE · New York Stock Exchange

Market cap (USD)$142.1B
SectorHealthcare
CountryUS
Data as of2025-12-29
Moat score
58/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pfizer Inc.'s moat claims, evidence, and risks.

View PFE analysis

Comparison highlights

  • Moat score gap: DSM-Firmenich AG leads (63 / 100 vs 58 / 100 for Pfizer Inc.).
  • Segment focus: DSM-Firmenich AG has 4 segments (31% in Perfumery & Beauty); Pfizer Inc. has 5 segments (47.4% in Primary Care).
  • Moat breadth: DSM-Firmenich AG has 10 moat types across 4 domains; Pfizer Inc. has 8 across 3.

Primary market context

DSM-Firmenich AG

Perfumery & Beauty

Market

B2B fragrances, perfumery ingredients, and beauty ingredients

Geography

Global

Customer

Consumer brands (fine fragrance, personal care, home care) and beauty brands

Role

Ingredient supplier / fragrance house (co-creation + ingredient palette)

Revenue share

31%

Pfizer Inc.

Primary Care

Market

Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)

Geography

Global

Customer

Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement

Role

Innovator biopharma (R&D + manufacturing + commercialization)

Revenue share

47.4%

Side-by-side metrics

DSM-Firmenich AG
Pfizer Inc.
Ticker / Exchange
DSFIR - Euronext Amsterdam
PFE - New York Stock Exchange
Market cap (USD)
n/a
$142.1B
Sector
Materials
Healthcare
HQ country
CH
US
Primary segment
Perfumery & Beauty
Primary Care
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
63 / 100
58 / 100
Moat domains
Supply, Demand, Legal, Network
Legal, Demand, Supply
Last update
2025-12-29
2025-12-29

Moat coverage

Shared moat types

IP Choke PointCompliance Advantage

DSM-Firmenich AG strengths

Supply Chain ControlTraining Org Change CostsScope EconomiesLearning Curve YieldDesign In QualificationService Field NetworkEcosystem ComplementsData Workflow Lockin

Pfizer Inc. strengths

Procurement InertiaGovernment Contracting RelationshipsCapex Knowhow ScaleLong Term ContractsOperational ExcellenceEmbedded R&D partnership platform

Segment mix

DSM-Firmenich AG segments

Full profile >

Perfumery & Beauty

Oligopoly

31%

Taste, Texture & Health

Oligopoly

25.4%

Health, Nutrition & Care

Competitive

17.3%

Animal Nutrition & Health

Competitive

26%

Pfizer Inc. segments

Full profile >

Primary Care

Oligopoly

47.4%

Specialty Care

Oligopoly

26.2%

Oncology

Competitive

24.5%

Pfizer CentreOne

Competitive

1.8%

Pfizer Ignite

Competitive

0.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.